Krystal Biotech ( (KRYS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Krystal Biotech’s stock has surged following the FDA’s approval of an updated label for Vyjuvek, which now includes use for infants and at-home administration, significantly boosting its market potential. Analysts are optimistic about Vyjuvek’s enhanced revenue prospects and its strengthened position in treating DEB, though some price targets have been adjusted due to broader market conditions. Additionally, the company’s strategic decision to prioritize inhaled KB707 and pause certain trials has also played a role in the stock’s evaluation.
More about Krystal Biotech
YTD Price Performance: -8.19%
Average Trading Volume: 354,922
Technical Sentiment Signal: Hold
Current Market Cap: $4.16B
For further insights into KRYS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.